EA200601212A1 - Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение - Google Patents

Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение

Info

Publication number
EA200601212A1
EA200601212A1 EA200601212A EA200601212A EA200601212A1 EA 200601212 A1 EA200601212 A1 EA 200601212A1 EA 200601212 A EA200601212 A EA 200601212A EA 200601212 A EA200601212 A EA 200601212A EA 200601212 A1 EA200601212 A1 EA 200601212A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
phosphodesterase
inhibitors
obtaining
therapeutic application
Prior art date
Application number
EA200601212A
Other languages
English (en)
Inventor
Мустафа Абаргаз
Стефано Бьонди
Жером Дюрантон
Эмманюэлль Лимантон
Чезаре Мондадори
Патрик Вагнер
Original Assignee
Нэрозд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нэрозд filed Critical Нэрозд
Publication of EA200601212A1 publication Critical patent/EA200601212A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms

Abstract

Изобретение относится к соединениям формулы (I), обладающим PDE2 ингибиторной активностью, также как к терапевтическим способам введения указанных соединений, в частности, для лечения различных заболеваний центральной или периферической нервной системы. Кроме того, оно касается фармацевтических композиций, содержащих указанные соединения, и способов приготовления указанных соединений. Соединения общей формулы (I)
EA200601212A 2003-12-23 2004-12-23 Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение EA200601212A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03293309A EP1548011A1 (en) 2003-12-23 2003-12-23 Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof
PCT/IB2004/004362 WO2005063723A1 (en) 2003-12-23 2004-12-23 Benzo`1,4 ! diazepin-2-one derivatives as phosphodiesterase pde2 inhibitors, preparation and therapeutic use thereof

Publications (1)

Publication Number Publication Date
EA200601212A1 true EA200601212A1 (ru) 2006-10-27

Family

ID=34530833

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200601212A EA200601212A1 (ru) 2003-12-23 2004-12-23 Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение

Country Status (11)

Country Link
US (1) US7410963B2 (ru)
EP (2) EP1548011A1 (ru)
JP (1) JP2007516276A (ru)
CN (1) CN1898217A (ru)
AU (1) AU2004309173A1 (ru)
BR (1) BRPI0418099A (ru)
CA (1) CA2548318A1 (ru)
EA (1) EA200601212A1 (ru)
IL (1) IL176072A0 (ru)
WO (1) WO2005063723A1 (ru)
ZA (1) ZA200606009B (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008516975A (ja) * 2004-10-19 2008-05-22 スミスクライン ビーチャム コーポレーション 化合物
EP1749824A1 (en) * 2005-08-03 2007-02-07 Neuro3D Benzodiazepine derivatives, their preparation and the therapeutic use thereof
EP2058304A4 (en) * 2006-08-25 2012-10-10 Nippon Chemiphar Co P2X4 RECEPTOR ANTAGONIST
WO2009037302A1 (en) * 2007-09-18 2009-03-26 Via Pharmaceuticals, Inc. 5-substituted-1, 4-benz0diazepines as phosphodiesterase inhibitors
WO2009157196A1 (ja) 2008-06-25 2009-12-30 武田薬品工業株式会社 アミド化合物
US8927602B2 (en) * 2009-11-06 2015-01-06 Sk Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
AU2010316106B2 (en) 2009-11-06 2015-10-22 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US9540379B2 (en) 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
US20140045856A1 (en) 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
WO2015106032A1 (en) 2014-01-08 2015-07-16 Intra-Cellular Therapies, Inc. Products and pharmaceutical compositions
SI3597649T1 (sl) 2014-04-23 2022-04-29 Dart Neuroscience Llc Sestavki, ki vsebujejo substituirane (1,2,4)triazolo(1,5-a)pirimidin-7-ilne spojine, kot zaviralci pde2
US10239882B2 (en) 2014-11-05 2019-03-26 Dart Neuroscience (Cayman) Ltd. Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors
JP6608933B2 (ja) 2014-12-06 2019-11-20 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2016090380A1 (en) 2014-12-06 2016-06-09 Intra-Cellular Therapies, Inc. Organic compounds
WO2016145614A1 (en) 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Triazolyl pyrimidinone compounds as pde2 inhibitors
US10287269B2 (en) 2015-03-26 2019-05-14 Merck Sharp & Dohme Corp. Pyrazolyl pyrimidinone compounds as PDE2 inhibitors
EP3291817B1 (en) 2015-05-05 2019-10-02 Merck Sharp & Dohme Corp. Heteroaryl-pyrimidinone compounds as pde2 inhibitors
WO2016183741A1 (en) 2015-05-15 2016-11-24 Merck Sharp & Dohme Corp. Pyrimidinone amide compounds as pde2 inhibitors
WO2016191935A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016192083A1 (en) 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Dihydropyrazolopyrimidinone compounds as pde2 inhibitors
EP3313852B1 (en) 2015-06-25 2021-01-20 Merck Sharp & Dohme Corp. Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors
WO2017000277A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
WO2017000276A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
EP3156405A1 (en) 2015-10-13 2017-04-19 Boehringer Ingelheim International GmbH Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide
JP2021504466A (ja) 2017-11-23 2021-02-15 オスロ ウニヴェルシティ ホスピタル ホーエフ 頻脈の治療
UA119735C2 (uk) * 2018-12-20 2019-07-25 Анатолій Семенович Редер Фармацевтична сполука, спосіб її отримання та застосування як лікарського засобу
CN111995576A (zh) * 2020-08-31 2020-11-27 三峡大学 多取代含氮杂环化合物的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2824065A1 (fr) * 2001-04-26 2002-10-31 Neuro3D Composes inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations
AU2002317910B2 (en) * 2001-06-07 2008-06-19 Via Pharmaceuticals, Inc. Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof

Also Published As

Publication number Publication date
US7410963B2 (en) 2008-08-12
CA2548318A1 (en) 2005-07-14
CN1898217A (zh) 2007-01-17
BRPI0418099A (pt) 2007-04-17
IL176072A0 (en) 2006-10-05
ZA200606009B (en) 2007-12-27
EP1548011A1 (en) 2005-06-29
EP1697332A1 (en) 2006-09-06
JP2007516276A (ja) 2007-06-21
US20070123519A1 (en) 2007-05-31
AU2004309173A1 (en) 2005-07-14
WO2005063723A1 (en) 2005-07-14

Similar Documents

Publication Publication Date Title
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
EA200601239A1 (ru) Замещённые хинолиновые соединения
EA200700362A1 (ru) Конъюгат, содержащий антивирусное соединение, в частности ингибирующее вич, фармацевтическая композиция и набор стандартной дозы лекарственного препарата на его основе, способ ингибирования с его помощью
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
EA200701296A1 (ru) 3,5-дизамещенные и 3,5,7-тризамещенные 3h-оксазоло- и 3h-тиазоло[4,5-d] пиримидин-2-оны и их пролекарства
TW200611695A (en) Pyrrolopyridine derivatives
ATE396973T1 (de) Benzylether- und benzylamino-beta-sekretase- hemmer zur behandlung von alzheimer-krankheit
EP1841426A4 (en) TERTIARY CARBINAMINES INCLUDING SUBSTITUTED HETEROCYCLES AS BETA SECRETASE INHIBITORS AND FOR THE TREATMENT OF ALZHEIMER'S DISEASE
DE60225556D1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
MX2007003013A (es) Amidas biciclicas como inhibidores de cinasa.
TW200606162A (en) Pyrazolopyridine derivatives
IL184898A0 (en) Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
MXPA06011327A (es) Azaindoles utiles como inhibidores de jak y otras proteinas cinasas.
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE451376T1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
DE502005008971D1 (de) Substituierte 1,4,8-triazaspiroä4.5 decan-2-on-verbindungen zur behandlung von fettsucht
EP1817312A4 (en) MACROCYCLIC AMINIOPYRIDYL BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER
ATE517861T1 (de) Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
MXPA05007462A (es) Derivados de pirrolopiridazina.
UA87494C2 (en) Azaindoles useful as inhibitors of jak and other protein kinases
TW200740808A (en) Inhibiteurs de proteines kinases
ATE538796T1 (de) Piperidin- und pyrrolidin-beta-secretase-hemmer zur behandlung von alzheimer-krankheit
MXPA06014182A (es) Nucleosidos de 3-??-d-ribofuranosiltiazolo[4,5-d]piridimina y usos de los mismos.
ATE432936T1 (de) Imidazotriazin verbindungen zur behandlung von krebserkrankungen